Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study

  title={Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study},
  author={Francesco Bartoli and Daniele Cavaleri and Tommaso Callovini and Ilaria Riboldi and Cristina Crocamo and Armando D’Agostino and Giovanni Martinotti and Federico Bertolini and Giovanni Ostuzzi and Corrado Barbui and Giuseppe Carr{\`a}},
  journal={Psychiatry Research},
3 Citations

Factors Associated with Medication Adherence to Long-Acting Injectable Antipsychotics: Results from the STAR Network Depot Study.

It is suggested that quality of patient-clinician relationship and tailored psychoeducational strategies may positively affect adherence in people undergoing psychopharmacological treatment, including LAI.

Review On: Recent Trends in Antipsychotic Formulations

The presented artile describes in detail the about recent trends in the formulation aspects of antipsychotic formulations and their mode of action.



Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison

There may be relative advantages for AOM over PP in the short-term treatment of schizophrenia, within the context of the inherent limitations of the current analysis.

Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate

The introduction of ALAI had a substantial impact on long-term clinical outcomes in this naturalistic cohort; more than half of patients continued treatment and had no admission during 2 years of follow up.

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting

The results suggest that both first- and second-generation LAI-APDs represent important therapeutic options, useful for improving schizophrenia’s clinical course and its economic burden.

Clinical correlates of paliperidone palmitate and aripiprazole monohydrate prescription for subjects with schizophrenia-spectrum disorders: findings from the STAR Network Depot Study

Clinicians may be more prone to prescribe PPM1, rather than aripiprazole monohydrate, to subjects showing higher overall symptom severity, including positive and negative symptoms.

Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study

Investigating variables associated with initiation of treatment with the long-acting injectables paliperidone palmitate and aripiprazole LAI in Medicaid patients with schizophrenia found patients who initiated LAi-PP had greater prior use of medical services than LAI-AP patients.

Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.

LAI formulations of palipersidone, aripiprazole, olanzapine, and paliperidone showed the highest effect sizes and certainty of evidence for both relapse prevention and acceptability, and should inform frontline clinicians and guidelines.

Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate

Consistently greater improvements were observed with aripiprazole once-monthly 400 mg vs paliperidone palmitate across all measures, and partial correlations between scales demonstrate the multidimensionality of various measures of improvement.

Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?

Paliperidone palmitate was more likely to be prescribed in patients with more frequent and lengthy hospital admissions prior to initiation than other cheaper LAI antipsychotics, but the absence of differences in outcomes after initiation indicates that paliperid one palMITate was not more effective than other cheap LAI anti-psychotic drugs.

Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic Study

Clinicians should be aware that LAI discontinuation is a frequent occurrence and LAI choice should be carefully discussed with the patient, taking into account individual characteristics and possible obstacles related to the practicalities of each formulation.